Addex Therapeutics (GB:0QNV) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Addex Therapeutics reported a provisional net loss of CHF 1.5 million for the third quarter of 2024, affected by the prior quarter’s one-time gain from a partial business sale, while maintaining a nine-month net profit of CHF 8.3 million. The company’s cash position stands at CHF 3.3 million as of the end of September. Investors are closely watching the upcoming final results and business update scheduled for November 22, 2024.
For further insights into GB:0QNV stock, check out TipRanks’ Stock Analysis page.
